IS THE RISK OF HCC FAVORABLY OR UNFAVORABLY INFLUENCED BY HCV THERAPY WITH DAAS?

Cabibbo Giuseppe; Craxi Antonio

首页> 外文期刊>Liver international : >IS THE RISK OF HCC FAVORABLY OR UNFAVORABLY INFLUENCED BY HCV THERAPY WITH DAAS?

【24h】

IS THE RISK OF HCC FAVORABLY OR UNFAVORABLY INFLUENCED BY HCV THERAPY WITH DAAS?

机译：HCC是否有利或不利地受到大阪治疗的不利影响的风险？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Liver international :》 |2019年第12期|共3页
作者
Cabibbo Giuseppe; Craxi Antonio;
展开▼
作者单位

Univ Palermo Dipartimento Biomed Med Interna &

Specialist Sect Gastroenterol &

Hepatol DIBIMIS;

Univ Palermo Dipartimento Biomed Med Interna &

Specialist Sect Gastroenterol &

Hepatol DIBIMIS;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词

相似文献

外文文献
中文文献
专利

1. IS THE RISK OF HCC FAVORABLY OR UNFAVORABLY INFLUENCED BY HCV THERAPY WITH DAAS? [J] . Cabibbo Giuseppe, Craxi Antonio Liver international : . 2019,第12期

机译：HCC是否有利或不利地受到大阪治疗的不利影响的风险？
2. Update on the Risk of Primary and Recurrent HCC?With the Use of DAA Therapy for HCV Infection [J] . Jordan Feld MD MPH Gastroenterology & Hepatology . 2019,第6期

机译：使用DAA疗法治疗HCV感染的原发性和复发性HCC风险更新
3. Treatment of HCV with DAAs in cirrhosis: Risk of early de novo hepatocellular carcinoma (HCC) and impact of HCC on SVR. [J] . Sterling Richard K., Patel Vaishali, Kumral Dennis, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：治疗肝硬化中DAAs的HCV：早期Novo肝细胞癌（HCC）的风险及HCC对SVR的影响。
4. An ensemble feature extraction classifier for the analysis of integrated data of HCV-HCC related DNA microarray [C] . Eid Salwa, Youssif Aliaa, Kassim Samar, 2012 IEEE EMBS Conference on Biomedical Engineering and Sciences. . 2012

机译：整体特征提取分类器，用于分析HCV-HCC相关DNA微阵列的整合数据
5. Baseline Toronto HCC Risk Index (THRI) and Albumin Predict Low Risk of Hepatocellular Carcinoma (HCC) after Sustained Virological Response (SVR) in HCV Infection [D] . Lau, Jason. 2019

机译：基线多伦多HCC风险指数（THRI）和白蛋白预测HCV感染持续病毒响应（SVR）后肝细胞癌（HCC）的低风险
6. Update on the Risk of Primary and Recurrent HCC With the Use of DAA Therapy for HCV Infection [O] . Jordan Feld 2019

机译：使用DAA治疗HCV感染的原发性和复发性HCC风险更新
7. Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis [O] . Friederike Ebel, Katja Deterding, Kerstin Port, 2019

机译：字母：DAA治疗后的5年的长期随访研究证实，在欧洲中央欧洲HCV患者肝硬化患者中降低了HCC风险

IS THE RISK OF HCC FAVORABLY OR UNFAVORABLY INFLUENCED BY HCV THERAPY WITH DAAS?

著录项

相似文献

相关主题

期刊订阅